Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan upgrades Genuit, sees risk/reward as more favourable

(Sharecast News) - JPMorgan Cazenove upgraded Genuit - formerly Polypipe - on Wednesday, to 'overweight' from 'neutral' and lifted the price target to 490p from 450p as it rolled forward its valuation to December 2026 from June 2026. The bank said that in its initiation in October 2024, while it was positive on the mid-term outlook at Genuit, it thought the relative re-rating in the shares had gone too far, especially given JPM's more cautious view on the pace of a recovery in end markets.

Since then, the shares have de-rated around 20% relative to JPM's coverage and now trade at close to their widest discount in a decade to other residential-exposed names in the bank's coverage.

"With forecasts and end markets having stabilised, and some green shoots appearing, particularly in new build resi, we now see risk/ reward as more favourable; and in the mid-term, see more than 30% earnings upside to our forecasts (pre any M&A)," JPM said.

Genuit is a manufacturer of plastic piping systems for use in the residential, commercial, civils and infrastructure sectors.

At 0920 BST, the shares were up 6.6% at 403.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.